Truist Financial’s Meridian Bioscience Inc VIVO Stock Holding History

Truist Financial’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,546	Closed	-$382K	–	2712
2022 Q2	$382K	Buy	+12,546	New	+$339K	﹤0.01%	2077

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truist Financial's VIVO Position: Q3 2022 in Review

Truist Financial sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 12,546 shares — an estimated $382K sold.

Truist Financial first reported a position in VIVO in Q2 2022 and held it in 1 quarter. The position peaked at $382K in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

Truist Financial reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
Truist Financial sold 12,546 Meridian Bioscience Inc shares in Q3 2022, an estimated $382K.
Truist Financial first reported a position in Meridian Bioscience Inc in Q2 2022 and held it in 1 quarter.
Truist Financial's Meridian Bioscience Inc position peaked at $382K in Q2 2022.
203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Truist Financial's 13F filing for Q3 2022, filed 26 Oct 2022.